US Stock MarketDetailed Quotes

RLYB Rallybio

Watchlist
  • 1.010
  • +0.060+6.29%
Close Jan 3 16:00 ET
  • 1.000
  • -0.010-0.99%
Post 20:01 ET
41.90MMarket Cap-0.64P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 10, 2024 07:01
    NEWS
    $Rallybio (RLYB.US)$
    Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
    Tuesday, 10th December at 8:00 am
    Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at ...
    Jaguar8
    Jaguar8
    Dec 2, 2024 07:16
    NEWS
    $Rallybio (RLYB.US)$
    Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
    Monday, 2nd December at 8:00 am
    -- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study –
    -- Manufacturing Process Enhancements Expected to Further Improve RLYB116 Tolerability --
    Trytosaveabit
    Trytosaveabit
    Nov 27, 2024 07:03
    Update
    $Rallybio (RLYB.US)$ Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
    3 MINUTES AGO, 8:00 AM EST
    VIA BUSINESSWIRE
    — Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial —
    Jaguar8
    Jaguar8
    Nov 27, 2024 07:02
    NEWS
    $Rallybio (RLYB.US)$
    Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
    Rallybio announced the publication of a manuscript detailing target-mediated drug disposition (TMDD) modeling used to determine RLYB212 dosing for pregnant women.
    The model incorporates pregnancy-related physiological changes and will be evaluated in their recently initiated Phase 2 clinical trial. RLYB212 is being developed ...
    Jaguar8
    Jaguar8
    Nov 21, 2024 07:05
    NEWS
    $Rallybio (RLYB.US)$
    Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
    — Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT —
    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk ...
Read more
Heat List
US
Overall
Symbol
Price
% Chg

No Data